We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » TEVA, ROXANE LABS RECEIVE FDA APPROVAL TO MARKET GENERIC ZOLOFT

TEVA, ROXANE LABS RECEIVE FDA APPROVAL TO MARKET GENERIC ZOLOFT

July 3, 2006

The FDA has given Israel-based Teva Pharmaceutical and Ohio-based Roxane Laboratories the go-ahead to market generic versions of Pfizer's blockbuster antidepressant Zoloft, the agency said June 30, the same day Pfizer's patent expired.

U.S. sales of Zoloft (sertraline) -- the sixth highest-selling brand drug in the U.S. -- were more than $2.6 billion in 2005, the FDA said. Teva plans to launch its Zoloft equivalent in late July. Roxane has not yet announced when it will launch its version.

Israeli drugmaker Teva will market the drug in 25-, 50- and 100-mg tablets. Roxane will market a 20-mL liquid concentrate Zoloft equivalent (sertraline HCl). Sertraline tablets are indicated to treat depression while liquid sertraline is indicated to treat depression and some anxiety disorders.

Teva and Roxane were the first companies to file applications containing a Paragraph IV certification for the Zoloft products they each plan to market, and each received 180 days of marketing exclusivity for their products. A Paragraph IV certification claims the drug patent is invalid or would not be infringed on by the generic version of the drug.

KEYWORDS Daily International Pharma Alert

Upcoming Events

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

  • 08Mar

    Medical Device Cybersecurity: The Regulatory Landscape and How to Defend Your Practices During an Inspection

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Boston Scientific’s Single Use Ureteroscope Gets FDA Clearance

  • Gilead’s Trodelvy Gets Expanded Approval in Breast Cancer

  • AI Software to Improve Echocardiogram Images Gets FDA Clearance

  • Rocket Pharmaceuticals Gets RMAT Designation for Danon Disease Gene Therapy

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing